170 related articles for article (PubMed ID: 34493594)
1. Allosteric Inhibition of HER2 by Moesin-Mimicking Compounds Targets HER2-Positive Cancers and Brain Metastases.
Faure C; Djerbi-Bouillié R; Domingot A; Bouzinba-Segard H; Taouji S; Saidi Y; Bernard S; Carallis F; Rothe-Walther R; Lenormand JL; Chevet E; Bourdoulous S
Cancer Res; 2021 Nov; 81(21):5464-5476. PubMed ID: 34493594
[TBL] [Abstract][Full Text] [Related]
2. Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2-positive cancers.
Blasquez L; Bouzinba-Segard H; Bourdoulous S; Faure C
Mol Oncol; 2023 Oct; 17(10):1981-1999. PubMed ID: 36912768
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.
Gril B; Palmieri D; Qian Y; Smart D; Ileva L; Liewehr DJ; Steinberg SM; Steeg PS
Clin Cancer Res; 2011 Jan; 17(1):142-53. PubMed ID: 21081656
[TBL] [Abstract][Full Text] [Related]
5. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
6. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
7. Cooperation of neurotrophin receptor TrkB and Her2 in breast cancer cells facilitates brain metastases.
Choy C; Ansari KI; Neman J; Hsu S; Duenas MJ; Li H; Vaidehi N; Jandial R
Breast Cancer Res; 2017 Apr; 19(1):51. PubMed ID: 28446206
[TBL] [Abstract][Full Text] [Related]
8. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
[TBL] [Abstract][Full Text] [Related]
9. Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies.
Goyette MA; Stevens LE; DePinho CR; Seehawer M; Nishida J; Li Z; Wilde CM; Li R; Qiu X; Pyke AL; Zhao S; Lim K; Tender GS; Northey JJ; Riley NM; Long HW; Bertozzi CR; Weaver VM; Polyak K
Proc Natl Acad Sci U S A; 2024 May; 121(20):e2322688121. PubMed ID: 38709925
[TBL] [Abstract][Full Text] [Related]
10. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Kodack DP; Chung E; Yamashita H; Incio J; Duyverman AM; Song Y; Farrar CT; Huang Y; Ager E; Kamoun W; Goel S; Snuderl M; Lussiez A; Hiddingh L; Mahmood S; Tannous BA; Eichler AF; Fukumura D; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3119-27. PubMed ID: 23071298
[TBL] [Abstract][Full Text] [Related]
11. Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer.
Maisel SA; Broka D; Atwell B; Bunch T; Kupp R; Singh SK; Mehta S; Schroeder J
J Transl Med; 2019 Jun; 17(1):201. PubMed ID: 31215437
[TBL] [Abstract][Full Text] [Related]
12. Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.
Zazo S; González-Alonso P; Martín-Aparicio E; Chamizo C; Luque M; Sanz-Álvarez M; Mínguez P; Gómez-López G; Cristóbal I; Caramés C; García-Foncillas J; Eroles P; Lluch A; Arpí O; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
Mol Cancer Ther; 2020 Aug; 19(8):1696-1707. PubMed ID: 32404410
[TBL] [Abstract][Full Text] [Related]
13. HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and
Elwaie TA; Abbas SE; Aly EI; George RF; Ali H; Kraiouchkine N; Abdelwahed KS; Fandy TE; El Sayed KA; Abd Elmageed ZY; Ali HI
J Med Chem; 2020 Dec; 63(24):15906-15945. PubMed ID: 33314925
[TBL] [Abstract][Full Text] [Related]
14. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
Puig T; Aguilar H; Cufí S; Oliveras G; Turrado C; Ortega-Gutiérrez S; Benhamú B; López-Rodríguez ML; Urruticoechea A; Colomer R
Breast Cancer Res; 2011; 13(6):R131. PubMed ID: 22177475
[TBL] [Abstract][Full Text] [Related]
15. Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases.
Bartova M; Hlavaty J; Tan Y; Singer C; Pohlodek K; Luha J; Walter I
Clin Exp Metastasis; 2017 Jun; 34(5):333-344. PubMed ID: 28624994
[TBL] [Abstract][Full Text] [Related]
16. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
17. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways.
Li X; Roslan S; Johnstone CN; Wright JA; Bracken CP; Anderson M; Bert AG; Selth LA; Anderson RL; Goodall GJ; Gregory PA; Khew-Goodall Y
Oncogene; 2014 Jul; 33(31):4077-88. PubMed ID: 24037528
[TBL] [Abstract][Full Text] [Related]
18. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Ding J; Yao Y; Huang G; Wang X; Yi J; Zhang N; Liu C; Wang K; Zhang Y; Wang M; Liu P; Ye M; Li M; Cheng H
Cancer Lett; 2020 Apr; 475():53-64. PubMed ID: 32006616
[TBL] [Abstract][Full Text] [Related]
19. Astrocytic IGFBP2 and CHI3L1 in cerebrospinal fluid drive cortical metastasis of HER2+breast cancer.
Ansari KI; Bhan A; Liu X; Chen MY; Jandial R
Clin Exp Metastasis; 2020 Jun; 37(3):401-412. PubMed ID: 32279122
[TBL] [Abstract][Full Text] [Related]
20. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
